Investment Snapshot

Mission Statement

A late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer.

Advaxis’ proprietary Lm targeted immunotherapy is a new approach toward an effective cancer vaccine.

Our Lm Technology has achieved safety and efficacy endpoints in early-stage trials and is the platform for our continued focus on the science, discovery, development and commercialization of cutting-edge cancer treatments.

Investment Snapshot

Flexible Platform Technology

  • Platform based on attenuated Lm (Listeria Monocytogenes)
  • Multiple approaches to impacting the immune system
  • Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours

Broad Pipeline with Four Franchises

  • 3 clinical stage programs: HPV-Associated Cancers, Prostate Cancer and ADXS-NEO individualized targeting in partnership with Amgen Inc.
  • Novel preclinical program: ADXS-HOT with multiple products targeting multiple cancers

Lead Program in Phase 3

  • HPV-targeting program includes axalimogene filolisbac and ADXS-DUAL
  • Ongoing registrational study of axalimogene filolisbac in high risk locally advanced cervical cancer
  • Registrational study of ADXS-DUAL in metastatic cervical cancer in combination with Opdivo® to start in 1H 2018

Ability to combine with other I-O agents

  • Demonstrated preclinical synergy with multiple checkpoint inhibitors and co-stimulatory agents
  • Three clinical trials in combination with PD-1/PDL-1 inhibitors

Strong Partnerships

  • 3 clinical collaborations evaluating combination therapies (Merck, AstraZeneca, Bristol-Myers Squibb)
  • Global collaboration for ADXS-NEO with Amgen on novel program targeting neoepitopes

Experienced Management Team

  • Deep and broad experience in pharmaceutical drug development and commercialization
Business Wire InvestorHQsm